Prostate cancer trials in Germany

In Germany 95 Also abroad 1480

95 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Berlin, Freiburg im Breisgau, Hamburg, Muenster, Nuertingen, Penzberg
Age
18 years and over
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00
Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Berlin, Bonn, Hamburg, Jena, Lübeck, Muenster, Munich, Schwerin
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 3Taking people
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Where
Dresden, Düsseldorf, Gronau, Hamburg, Leipzig, München, Münster, Rostock
Age
18 years and over
People
434 worldwide
Run by
ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584
Phase 1Taking people
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Where
Erlangen, Essen, München
Age
18 years and over
People
421 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00
Phase 3Taking people
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Brunswick, Duesseldorf, Duisburg, Essen, Frankfurt am Main, Hamburg, Heidelberg, Muenster, Munich, Nuertingen, Nuremberg
Age
18 years and over
People
1,203 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00
Phase 3Taking people
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Dresden, Duisburg, Essen, Hamburg, Munich, Nuertingen
Age
18 years and over
People
800 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00
No phaseNot yet taking people in Germany
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
Where
Berlin, München
People
50 worldwide
Run by
Aristotle University Of Thessaloniki
See details and how to joinNCT07888322
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Hamburg, Muenster, Nuertingen, Tuebingen
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Berlin, Cologne, Duisburg, Frankfurt Am Main, Hamburg, Luebeck, Mainz, Munich, Nuertingen, Nuremberg, Potsdam, Stuttgart
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Berlin, Deggendorf, Hamburg
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 1/2Taking people
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Where
Essen, Jena
Age
18 years and over
People
205 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07288359
Phase 1/2Taking people
Study to assess the safety and efficacy of the SpectraCure P18 System
Where
Brunswick
Age
18 years and over
People
26 worldwide
Run by
SpectraCure AB (publ)
See details and how to join2022-502285-24-00 · EU 2022-502285-24-00
Phase 2Not yet taking people in Germany
New diagnostic pathway in primary diagnosis of clinically significant prostate cancer adding PSMA-PET to mpMRI
Where
Augsburg, Munich
Age
18 years and over
People
150
Run by
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
See details and how to join2026-527906-19-00 · EU 2026-527906-19-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1Taking people
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
Where
Dresden, Wuerzburg
Age
18 years and over
People
26 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-524080-20-00 · EU 2025-524080-20-00
Phase 1Taking people
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Where
Dresden, Würzburg
Age
18 years and over
People
208 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07570979
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Aachen, Augsburg, Berlin, Bonn, Cologne, Essen, Muenster, Munich, Rostock
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Bergisch Gladbach, Berlin, Duisburg, Freiburg im Breisgau, Goettingen, Heidelberg, Munich, Nuertingen, Regensburg
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena, Kiel, Ulm, Würzburg
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
No phaseTaking people
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Where
Many Locations
Age
18 years and over
People
1,600 worldwide
Run by
Bayer
See details and how to joinNCT07344779
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe, München, Münster, Nuremberg, Rostock, Stuttgart, Tübingen, Würzburg
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 1/2Not yet taking people in Germany
A study of benfo‑oxythiamine added to Pluvicto® in adults with advanced prostate cancer whose disease is stable after two prior Pluvicto® cycles
Where
Essen, Muenster, Munich
Age
18 years and over
People
48
Run by
Benfovir AG
See details and how to join2026-527059-25-00 · EU 2026-527059-25-00
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Dresden, Essen, Halle Saale, Hamburg, Magdeburg, München, Nuertingen, Rostock, Ulm, Würzburg
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
Phase 2Not yet taking people in Germany
A study comparing Pluvicto® plus Standard of Care treatment with ADT and Nubeqa® vs. Standard of Care treatment with ADT and Nubeqa® in Patients with mHSPC
Where
Freiburg im Breisgau
Age
18 years and over
People
72
Run by
Medical Center - University Of Freiburg
See details and how to join2026-525520-20-00 · EU 2026-525520-20-00
Phase 1/2Taking people
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Where
Dresden, Essen, München, Stuttgart
Age
18 years and over
People
123 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00